查看文章

We read with interest the retrospective observational study investigating the short-term effect of oral anti-viral agents on United States Veterans aged 65 years and older who were at high risk of developing severe COVID-19. 1 Two groups, each composed of 1370 individuals, were identified based on the presence or absence of oral antivirals treatment (either molnupiravir or nirmatrelvir plus ritonavir [NMV-r]) using propensity score matching method to balance their baseline characteristics. Compared with the group not receiving oral antivirals, elderly patients receiving NMV-r or molnupiravir had a lower risk of hospitalization or death within 30 days of diagnosis (4.75% versus 10.2%; odds ratio [OR], 0.44, 95% CI, 0.32–0.60). 1 This finding was consistent with the meta-analysis o f seven studies by Zheng et al., 2 in which the OR of death or hospi-talization among COVID-19 patients in the NMV-r vs. control group was …